Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > i am surprised

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Apr 05, 2023 1:12pm

278 Views

Post# 35381389

i am surprised

we are not geting bid up today. we usually do on days like today. this is a safe and defensive place to park some cash. and doubly so when news could come out at anytime. maybe cause we no longer have an analyst pumping our stock now that mcwhirter is no longer on BNN, many people are just unaware.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China